Coumadin

DRUG4 trials

Sponsors

GlaxoSmithKline, Agency for Healthcare Research and Quality (AHRQ), Texas Cardiac Arrhythmia Research Foundation, Foundation University Islamabad

Conditions

Atrial FibrillationCerebral Venous ThrombosisDeep Vein ThrombosisDeep Venous ThrombosisFibrillation, AtrialHeart Valve ReplacementPulmonary EmbolismThromboembolism

Phase 2

Odiparcil For The Prevention Of Venous Thromboembolism

CompletedNCT00244725

GlaxoSmithKlineDeep Vein Thrombosis, Fibrillation, Atrial, Pulmonary Embolism +1

Start: 2005-09-30End: 2006-09-30Updated: 2017-05-02

Phase 3

Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

CompletedNCT01006876

Texas Cardiac Arrhythmia Research FoundationThromboembolism

Start: 2010-01-31End: 2014-04-30Updated: 2015-05-20

Unknown Phase

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

Agency for Healthcare Research and Quality (AHRQ)Atrial Fibrillation, Deep Venous Thrombosis, Heart Valve Replacement +1

Start: 2007-06-30End: 2008-05-31Target: 260Updated: 2007-06-11

Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis

Foundation University IslamabadCerebral Venous Thrombosis

Start: 2017-08-31End: 2018-09-30Target: 50Updated: 2017-06-19

Related Papers

Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management

Circulation2014-04-18480 citations